HROUS

Warehouse Temperature Mapping: Requirements for Canadian QA Managers

Advertisement

Before accepting routine monitoring positions, require a mapping study to document operating conditions, reproducible logger locations, calibration, traceable measurements and the findings supporting each proposed position. Treat these as recommended acceptance evidence, distinct from Canadian drug-storage obligations. [2][3]

Aerial view of industrial warehouses in Mexico City surrounded by residential areas and greenery.
Advertisement

Separate drug-storage obligations from study recommendations

Health Canada’s August 2020 GUI-0069 describes drug-storage obligations and mapping expectations. It is administrative guidance for covered drug products, has no force of law itself and does not override the Food and Drugs Act or Regulations. Scientifically justified alternative approaches may be considered. Use it in its drug-product context, not as a universal warehouse standard. [1]

Keep two categories separate when reviewing a proposal:

  • Drug-storage obligations and expectations: GUI-0069 describes the obligation under section C.02.015 to follow storage conditions approved by the person responsible for quality control, alongside labelled storage conditions. Its guidance calls for qualified storage areas, calibrated monitoring devices, recorded findings and mapping to identify locations most likely to leave the required range. [1]
  • Recommended study evidence: A risk-based protocol, reproducible positions, relevant calibration, traceable data and documented operating conditions support defensible conclusions. US Validation and GuideGxP provide technical recommendations, not Canadian statutory requirements. [2][3]

These sources establish no universal Canadian logger count, spacing, study duration or temperature range. Require a design justified against the products, usable storage volume and operating conditions—not a supposedly mandatory standard package. [1][2][3]

Advertisement

Define products, storage volume and acceptance criteria

Require the proposal to identify products or materials, intended use, approved storage conditions and other controlled environmental parameters. [2] For covered drugs, GUI-0069 specifies labelled storage conditions and conditions approved by the person responsible for quality control—not a generic warehouse temperature band. [1]

Define the study boundary before agreeing to the test plan:

  • Usable storage volume: identify racks, shelves, pallet positions and permitted heights; exclude space unavailable because of airflow restrictions, walls, doors or equipment. [2]
  • Operating conditions: document the loading range, access frequency and operating schedule the study will support. [2]
  • System boundary: identify heating, refrigeration, air handling, controls, monitoring, alarms, relevant utilities and backup or contingency arrangements. [2]

Ask for an approved protocol specifying responsibilities, acceptance criteria, stabilisation rules, sampling interval, duration, challenge tests, missing-data treatment and required report content. Duration should be justified against operating cycles and study objectives. [2] Declare corrections, measurement uncertainty and decision margins beforehand—not after seeing the results. [3]

For each test, ask which operating or storage decision it supports. The answer should connect the test to intended use, loading configuration or approved storage volume. [2]

Advertisement

Make every logger position reproducible

Ask for controlled drawings that locate each logger in three dimensions—not dots on a floor plan. US Validation recommends plan and elevation views where needed. [2]

  • Locate every measurement: require a unique location identifier, coordinates or equivalent fixed references, height and relevant rack, shelf or pallet position. Photographs support placement records but do not replace coordinates and identifiers. [2][3]
  • Show the surroundings: identify doors, exterior walls, supply and return airflow paths, evaporators, heat sources and restricted storage positions. [3]
  • Explain the selection: request a risk rationale addressing relevant upper and lower levels, dense loads, doors, separate HVAC zones, airflow features and known vulnerable locations. [2]
Advertisement

Distinguish representative product-position measurements from diagnostic readings beside walls or air discharges. [2][3] Identify free-air, between-pack and simulated-product measurements separately: GuideGxP cautions they are not interchangeable. Buffering can attenuate short temperature changes, while exposed probes can respond faster than a product core. [3]

Specify controls against movement, unintended surface contact and load obstruction. The final record should show installed positions and deviations from the plan. [2][3] Another qualified person should be able to reinstall each logger using the drawing and location record. [2]

Audit calibration and instrument-to-file traceability

Each temperature record should link to its location, logger or channel, calibration certificate, configuration and original data file. Require that chain in the handover package; graphs alone are insufficient evidence of traceability. [3]

Advertisement

For covered drug storage, GUI-0069 calls for monitoring devices to be calibrated at predetermined intervals and periodically checked against established limits. [1] The following checks are recommended technical evidence, not a separate universal Canadian certificate specification:

  • Calibration suitability: match instrument identity to its certificate; review calibrated points, operating range, resolution, corrections and uncertainty. Room-temperature calibration alone does not establish freezer suitability. [3]
  • Time alignment: confirm synchronisation and record the time zone, daylight-saving treatment and offsets so measurements can be matched to events. [3]
  • Data capture: assess the sampling interval alongside sensor response. Require battery, memory and data-recovery checks, retained configurations and a unique channel-to-position relationship. [3]

The protocol should define calibration requirements, uncertainty treatment and missing-data rules before testing. [2] Incorporate applicable corrections and uncertainty into the pass/fail decision rule; do not change allowances afterwards to secure a pass. If plausible values within measurement uncertainty would change the conclusion, require further evidence. [3]

Advertisement

Check loading, weather and operating events

Require evidence of credible warehouse use, not an unexplained label such as “normal operation.” An unusually favourable setup may pass without representing the intended conditions. [2][3]

  • Actual configuration: record load quantities, pallet arrangements, shifts, door activity, material movements, airflow and relevant equipment cycles, including departures from the approved configuration. [2][3]
  • Duration rationale: explain how the period captures relevant work patterns, recovery and equipment cycles—not merely how long the loggers run. [2][3]
  • Seasonal challenge: record external conditions and explain why they represent the exposure assessed. A summer or winter date alone does not demonstrate a meaningful challenge. [3]

Keep challenge tests equipment-specific. For drug-storage refrigerators and freezers, GUI-0069 lists qualification considerations including empty/full loading, door-opening recovery, power-loss holdover, alarm testing and sufficient time to capture compressor and defrost cycles. These are not a blanket test list for ordinary warehouses. [1]

Require a time-aligned event log identifying loading changes, door activity, equipment events and setup deviations. It should let the reviewer connect temperature changes to operating conditions rather than interpret readings without context. [3]

Advertisement

Require evidence for hot and cold zones

Begin with a data-quality check: completeness, chronological order, units, duplicate values, missing channels and gaps. Then review each measured location—not a room average—for minimum and maximum temperatures, time outside limits, recurrence and recovery, linked to recorded events. [3]

Keep “worst case” tied to the condition tested. The warmest stable-operating position may differ from the fastest-warming position during failure; the coldest position during pull-down may differ during defrost. Preserve those distinctions rather than collapse them into one hot-point or cold-point label. [2][3]

A colour map should distinguish measured locations from interpolated estimates and separate demonstrated storage volume from excluded zones. Require explanations for unresolved conditions. [3] Identifying warm and cold points alone does not establish complete equipment qualification. [2]

Advertisement

Connect findings to routine monitoring positions

Distinguish sensor roles: control sensors regulate the system, temporary mapping loggers characterise the storage volume, and permanent monitoring probes provide ongoing surveillance. [2]

GUI-0069 links monitoring-position selection to mapping that identifies locations most likely to depart from required conditions. [1] Require a position-by-position rationale connecting permanent probes to measured warm or cold behaviour, usable stock positions, airflow and relevant recovery or failure conditions. Neither the centre nor the door is automatically correct. [3][4]

For each proposed probe, check:

  • Observed vulnerability: which product location is vulnerable, and under what operating condition? [2][3]
  • Supporting evidence: which mapping logger, temperature history and event record support the finding? [3]
  • Monitoring position: where will the probe sit, and why should it detect the relevant behaviour? [2][3]
  • Storage restriction: which excluded zone, loading limit, clearance or access restriction accompanies the decision? [3]
  • Unresolved limitation: which loads, seasonal conditions or failure scenarios remain unsupported? [2][3]

Judge probe quantity by its documented coverage rationale, not a universal count. The report should state the limits of the tested conditions rather than imply coverage of untested scenarios. [2][3]

Advertisement

Check the final handover before acceptance

Make acceptance depend on complete evidence and implemented operating controls, not report delivery alone. [2][3] Check for:

  • Study records: approved protocol, deviations, criterion-by-criterion results and justified monitoring recommendations. [2][3]
  • Traceability: controlled as-installed drawings; links between instruments, calibration certificates and raw files; actual load, weather and event records. [3]
  • Usable restrictions: authorised zones, exclusions, clearances and heights translated into loading, access, recovery and failure-response instructions. Excluded positions should remain recognisable and unavailable for stock assignment in warehouse systems. [3]
  • Action closure: named owners, completion dates and implementation verification before relevant release, plus a walk-through with the people applying restrictions. [3]
  • Reassessment triggers: changes to racking, airflow, HVAC, inventory patterns, equipment, software or intended use. [3]

For covered drugs, connect instructions to documented excursion investigations and evidence-based stock-retention or disposal decisions. [1] As European background, Netherlands-based Temperature Mapping Europe recommends written agreements for outsourced storage or transport covering notification, escalation, calibration and maintenance responsibilities. Its guidance addresses EU GDP; it does not establish requirements for Canadian operations. [4]

Advertisement

References

  1. Guidelines for Temperature Control of Drug Products during Storage and Transportation (GUI-0069) – Canada.ca (canada.ca)
  2. Thermal Mapping Study Design and Qualification (usvalidation.com)
  3. Temperature Mapping of Pharma Warehouses and Cold Rooms – GuideGxP (guidegxp.com, 2026)
  4. GDP requirements for temperature mapping | Practical guide (temperaturemapping.eu)
Advertisement

Similar reads